SCHEMBL5367510

SCHEMBL5367510

O=C(O)c1ccc(NC(=S)NN=Cc2ccc3ccccc3c2O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.52
MAPT P10636 8/20 0.51
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
GAA P10253 4/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
XDH P47989 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
RCE1 Q9Y256 1/20 0.46
GCGR P47871 1/20 0.46
HKDC1 Q2TB90 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367508 1.00 HDAC8 (0.52) HDAC8MAPTNPC1RAB9AMEN1
SCHEMBL5357962 0.88 MAPT (0.52) HDAC8MAPTNPC1RAB9AMEN1
SCHEMBL5357969 0.88 MAPT (0.52) HDAC8MAPTNPC1RAB9AMEN1
SCHEMBL5365901 0.88 RAB9A (0.67) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5365899 0.88 RAB9A (0.67) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5362088 0.85 KMT2A (0.60) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5362082 0.85 KMT2A (0.60) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5361121 0.81 GAA (0.60) HDAC8MAPTNPC1RAB9AMEN1
SCHEMBL5361125 0.81 GAA (0.60) HDAC8MAPTNPC1RAB9AMEN1
SCHEMBL5372739 0.79 SIRT1 (0.57) HDAC8MAPTNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK HDAC8 4784/4885MAPT 4635/4885NPC1 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.